title: Comparison of relative cerebral blood volume and proton spectroscopy in patients with treated gliomas.
abstract: OBJECTIVE
  Elevated relative regional cerebral blood volume (rCBV) reflects the increased microvascularity that is associated with brain tumors. The purpose of this study was to investigate the potential role of rCBV in the determination of recurrent/residual disease in patients with treated gliomas.
  
  
  METHODS
  Thirty-one rCBV studies were performed in 19 patients with treated gliomas. All patients also had proton MR spectroscopy and conventional MR imaging. Regions of abnormality were identified on conventional MR images by two neuroradiologists and compared with rCBV and MR spectroscopic data. Metabolites and rCBV were quantified and compared in abnormal regions.
  
  
  RESULTS
  In high-grade tumors, rCBV values were proportional to choline in regions of tumor and nonviable tissue. Although the presence of residual/recurrent disease was often ambiguous on conventional MR images, the rCBV maps indicated regions of elevated vascularity in all low-grade tumors and in 12 of 17 grade IV lesions. Regions of elevated and low rCBV corresponded well with spectra, indicating tumor and nonviable tissue, respectively.
  
  
  CONCLUSIONS
  This study suggests that rCBV maps and MR spectroscopy are complementary techniques that may improve the detection of residual/recurrent tumor in patients with treated gliomas. Compared with the spectra, the rCBV maps may better reflect the heterogeneity of the tumor regions because of their higher resolution. The multiple markers of MR spectroscopy enable better discrimination between normal and abnormal tissue than do the rCBV maps.
authors.affiliation: Department of Radiology, University of California at San Francisco, 94143, USA.
authors.forename: R G
authors.initials: RG
authors.lastname: Henry
authors.forename: D B
authors.initials: DB
authors.lastname: Vigneron
authors.forename: N J
authors.initials: NJ
authors.lastname: Fischbein
authors.forename: P E
authors.initials: PE
authors.lastname: Grant
authors.forename: M R
authors.initials: MR
authors.lastname: Day
authors.forename: S M
authors.initials: SM
authors.lastname: Noworolski
authors.forename: J M
authors.initials: JM
authors.lastname: Star-Lack
authors.forename: L L
authors.initials: LL
authors.lastname: Wald
authors.forename: W P
authors.initials: WP
authors.lastname: Dillon
authors.forename: S M
authors.initials: SM
authors.lastname: Chang
authors.forename: S J
authors.initials: SJ
authors.lastname: Nelson
mesh_terms: D000328:Adult; D001224:Aspartic Acid / Q000031:analogs & derivatives / Q000032:analysis; D001810:Blood Volume / Q000502:physiology*; D001921:Brain / Q000098:blood supply*; D001932:Brain Neoplasms / Q000098:blood supply / Q000175:diagnosis / Q000628:therapy*; D002794:Choline / Q000032:analysis; D003131:Combined Modality Therapy; D005260:Female; D005910:Glioma / Q000098:blood supply / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis; D018365:Neoplasm, Residual / Q000175:diagnosis; D009389:Neovascularization, Pathologic / Q000175:diagnosis; D011183:Postoperative Complications / Q000175:diagnosis*
chemical_list: D001224:Aspartic Acid; C000179:N-acetylaspartate; D002794:Choline